1.Research and application of intelligent hyperspectral analysis technology for Chinese materia medica.
He WANG ; Shi-Yu LIU ; Hui WANG ; Wei LI ; Meng LYU
China Journal of Chinese Materia Medica 2023;48(16):4320-4327
With the development of imaging technology and artificial intelligence, hyperspectral imaging technology provides a fast, non-destructive, intelligent, and precise new method for the analysis of Chinese materia medica(CMM). This paper summarized the methods and applications of hyperspectral imaging technology combined with intelligent analysis technology in the field of CMM in recent years, focusing on the acquisition and preprocessing of hyperspectral data, intelligent analysis methods of hyperspectral data, and practical cases of these technologies in the field of CMM. Hyperspectral data of CMM can provide spectral information with nanometer-level resolution and rich spatial texture information simultaneously. This paper summarized the acquisition process, including black-and-white board calibration and region-of-interest extraction, and preprocessing methods including smoothing, differentiation, scale-space, and scattering correction. The feature extraction methods in terms of spectral, spatial, color, and texture were briefly described, and common modeling methods were summarized. Finally, this paper reviewed the research cases of the application of the above methods to the fields of CMM, such as authenticity identification, origin tracing, variety recognition, year identification, sulfur fumigation degree determination, and quantitative measurement.
Humans
;
Artificial Intelligence
;
Drugs, Chinese Herbal
;
Hyperspectral Imaging
;
Materia Medica
;
Medicine, Chinese Traditional
;
Technology
2.Discussion on discipline of herbalism.
Ying-Zhan YANG ; Bing LI ; Jia-Lun WANG ; Zi-Ling ZENG ; Wei ZHANG ; Hua-Min ZHANG
China Journal of Chinese Materia Medica 2023;48(23):6519-6525
Since the emergence of the term "materia medica", scholars have proposed different opinions on its concept. This term has been used to refer to traditional Chinese medicines, or medical books, or traditional pharmacology. Due to the differences in the concept of materia medica, scholars also have controversies about the concept of herbalism. Herbalism is usually understood as traditional Chinese pharmacology. After years of evolution, the term "herbalism" has now possessed the characteristics of an independent discipline, which can be defined as an applied basic discipline that comprehensively utilizes traditional and modern technological methods to study the formation, development, and changes of traditional pharmacology and reveal the basic theories and application laws of traditional medicine. At present, the research content of herbalism mainly includes three aspects: materia medica history, materia medica literature, and traditional pharmacology. This study explores the disciplinary concepts and main research content of herbalism based on a systematic review of the literature about the concepts of materia medica and herbalism, with the aim of attracting more attention to promote the establishment and development of the discipline of herbalism.
China
;
Drugs, Chinese Herbal
;
Herbal Medicine
;
Materia Medica
;
Medicine, Chinese Traditional
;
Technology
3.Textual research on Bambusae Concretio Silicea.
Xiang-He KONG ; Guang-Xi REN ; Yu-Bin XU ; Dan JIANG ; Chun-Sheng LIU
China Journal of Chinese Materia Medica 2023;48(24):6812-6816
By studying various ancient texts such as herbal classics and medical literature from different eras, it was found that there were discrepancies in the records about Bambusae Concretio Silicea(Tian Zhu Huang). In order to establish an accurate foundation, this research was based on ancient herbal literature and combined with plant morphology and investigative studies to examine its earliest mentions in ancient texts, nomenclature, medicinal properties, indications, and quality assessment standards. In the early records, Bambusae Concretio Silicea was referred to by several different names, such as "Zhu Huang" "Tian Zhu Huang" "Zhu Gao" "Zhu Tang", and "Zhu Huang". The earliest known formal usage of the name "Tian Zhu Huang" was found in the book Ri Hua-zi's Materia Medica(Ri Hua Zi Ben Cao). Throughout various ancient texts, the earliest recorded information about Bambusae Concretio Silicea also appeared in Ri Hua-zi's Materia Medica, not in Materia Medica of Sichuan(Shu Ben Cao) or other ancient texts. Ri Hua-zi's Materia Medica provided relevant descriptions of its origin, medicinal properties, and indications, albeit with some errors due to limited knowledge. However, this has been a valuable starting point for future research on Bambusae Concretio Silicea and holds pioneering significance in forming a mature system. As the research delved deeper, the medicinal properties of Bambusae Concretio Silicea have been consistent since Ri Hua-zi's Materia Medica, and the understanding has gradually improved through years of clinical verification. During the investigation process, the authors found limited records on the quality evaluation of Bambusae Concretio Silicea in ancient texts. Although the information is scarce, it serves as a foundational basis for establishing corresponding quality grading standards for Bambusae Concretio Silicea in the future.
Materia Medica
;
China
;
Medicine, Chinese Traditional
4.Historical investigation on paradigm of "species standardization" of Chinese herbal medicine.
China Journal of Chinese Materia Medica 2023;48(1):273-278
The paradigm can be summarized as the same methodological principles followed by the members of the learning community who received common education, training, and edification in the common social and historical stage, and had common academic views, concepts, and terms. The "species standardization" paradigm of botanical drugs in China has experienced the period of non-standardization of names(the end of the Warring States period), the period of multi-dimensional textual research paradigm of traditional materia medica(from the end of the Warring States period to 1930s), and periods of modern plant taxonomy system research paradigm(from 1930s to the present). The multi-dimensional textual research paradigm of traditional materia medica is characterized by the textual research of species in different regions and years based on the classification of the natural attributes and the habit of correspondence between names and materials, from the multi-dimensional investigation of the name, appearance, color, smell, texture, growth environment, efficacy, and morphological characteristics of medicinal materials, to find the correspondence between names and materials. The purpose of the progress in traditional species standardization is practicality for humans, and there is a lack of systematic research on the classification and naming principles in line with its laws from the plant itself, resulting in inaccurate research results. The research paradigm of modern plant taxonomy is herbal research. The characteristics of this paradigm are using plant taxonomy knowledge to conduct textual research to confirm the species of the drug and calibrate the scientific name by the double name method, based on the plant morphology, harvest season, origin distribution, ecological habits, names, drug efficacy, and other data in the lite-rature of previous dynasties. This paradigm combines the knowledge of traditional materia medica and modern plant taxonomy, and the results of species research are accurate.
Humans
;
Drugs, Chinese Herbal
;
Materia Medica
;
Medicine, Chinese Traditional
;
China
;
Knowledge
5.Traditional Chinese medicine health care from "long term taking" drugs in Shen Nong's Classic of Materia Medica.
Qian YU ; Peng ZHOU ; Jian-Jun ZHANG ; Lin-Yuan WANG ; Peng-Wei ZHUANG ; Yan-Jun ZHANG
China Journal of Chinese Materia Medica 2023;48(3):835-840
"Taking drugs for a long term" is a qualitative expression of medication method based on the efficacy and safety of Chinese medicine, and the study on it is conducive to the full utilization of the efficacy and rational use of drugs. There are 148 drugs that can be taken for a long time recorded in Shen Nong's Classic of Materia Medica, accounting for 41% of the total drugs. This paper analyzed three-grade classification, natural qualities, four properties and five flavors, and efficacy features of the "long-term taking" drugs(LTTD), thus exploring the herbal source of traditional Chinese medicine health care and the rationality of effect accumulation by long-term taking. It was found that there were more than 110 top-grade LTTD in Shen Nong's Classic of Materia Medica, most of which were herbs, with sweet flavor, flat property, and no toxicity. The efficacies were mainly making body feel light and agile(Qingshen) and prolonging life. Eighty-three LTTD were included in the Chinese Pharmacopoeia(2020 edition). In the modern classification, tonic LTTD accounted for the most, followed by damp-draining diuretic LTTD and exterior-releasing LTTD. Twenty LTTD were included in the "List of Medicinal and Edible Products" and 21 were in the "List of Products Used for Health-care Food", involving in various modern health care effects, such as enhancing immunity, assisting in reducing blood lipids, and anti-oxidation. Shen Nong's Classic of Materia Medica is the classic source of traditional Chinese medicine health care, and its medication thought of taking drugs for a long term to accumulate effects has guiding significance for the regulation of sub-health and chronic diseases nowadays. The efficacy and safety of LTTD have been examined in practice for a long time, and some of the drugs are edible, which is unique in the whole cycle of health-care service, especially in line with the health-care needs in the aging society under the concept of Big Health. However, some records in the book are limited by the understanding of the times, which should be scientifically studied according to the Chinese Pharmacopoeia and the related regulations and technical requirements, under the attitude of eliminating falsifications and preserving the truth and keeping the right essence, so as to achieve further improvement, innovation, and development.
Humans
;
Delivery of Health Care
;
Materia Medica
;
Medicine, Chinese Traditional
6.Slicing specifications in general rule of processing in Chinese Pharmacopoeia from slicing development of Chinese materia medica processed product and thinking and suggestion on slicing techniques.
Meng-Hua WU ; Ying ZHANG ; Tian-Zhu JIA ; Xiang-Ri LI ; Ming YANG ; Hui CAO
China Journal of Chinese Materia Medica 2023;48(6):1691-1699
Slicing is critical in the processing of Chinese materia medica(CMM) processed product and the specification(thickness) is closely related to the quality of the decoction. On the basis of clarifying the concept and evolution of slicing of CMM processed product by reviewing the Chinese herbal classics of the past dynasties and general rules of local processing standards, this study discussed the development history of slicing specifications in general rules of Chinese Pharmacopoeia(2020 edition), analyzed the current situation and key problems, and proposed the thinking and suggestion on promoting the sound development of slicing of CMM processed product. Since 2000, the slicing thickness of CMM processed product in the general rules of local CMM processed product processing specifications newly revised and issued by 27 provinces, autonomous regions, and municipalities has been consistent with that in the general rules of the Chinese Pharmacopoeia(2020 edition). The standard that the thickness of extremely thin pieces is less than 0.5 mm is rarely retained, and the pieces in 0.5-1 mm thickness have not been found on the market, which is consistent with the provisions of the general rules of the Chinese Pharmacopoeia. This study can provide a historical and modern basis for the rationality of slicing of CMM processed product.
Materia Medica
;
Drugs, Chinese Herbal
;
Medicine, Chinese Traditional
;
Reference Standards
7.Medicinal evolution and modern research progress on Mume Fructus.
Ying ZHANG ; Qiong QU ; Xiao-Mei ZHAO ; Pei-Yuan ZHAO ; Xin-Bo ZHANG ; Jin-Qing QIU ; Xi DUAN ; Xiao SONG
China Journal of Chinese Materia Medica 2023;48(14):3753-3764
Prunus mume is an edible and medicinal material, and Mume Fructus is its processed product, which was first recorded in Shennong's Classic of Materia Medica(Shen Nong Ben Cao Jing). It is an effective drug for stopping diarrhea with astringents and promoting fluid production to quiet ascaris. By consulting the ancient herbal works of the past dynasties, modern codes, and other rela-ted literature, this paper sorted out the medicinal evolution of Mume Fructus, examined the ancient efficacy of Mume Fructus and the main indications, and summarized the inclusion of Mume Fructus in national and provincial standards. It is recorded in the ancient herbal works of the past dynasties that Mume Fructus can be processed by various methods such as roasting, stir-frying or micro-frying, stir-frying with charcoal, single steaming, steaming with wine, and steaming after soaking in wine or vinegar, and prepared into pills, powders, and ointments, which are used in the treatment of fatigue, diabetes, malaria, dysentery, ascariasis, and other diseases. Mume Fructus has been included in nine editions of Chinese Pharmacopoeia and 19 provincial and municipal preparation specifications. The processing method of Mume Fructus is determined, namely, clean P. mume should be softened by moistening in water or steaming and pitted. By reviewing the effects of processing on its chemical composition, pharmacological effects, and its modern clinical application, this paper identified the following issues. The ancient application methods of Mume Fructus are diverse but less commonly used in modern times, there is a lack of standardized research on the processing, and the research on the changes caused by the difference in Mume Fructus before and after processing is not deep. Therefore, it is necessary to further investigate the change pattern of its chemical composition before and after processing and its correlation between its medicinal activity to standardize the processing technology and provide a solid basis for the use of Mume Fructus in parts and its quality control.
Drugs, Chinese Herbal/pharmacology*
;
Materia Medica/analysis*
;
Fruit/chemistry*
;
Quality Control
;
Prunus/chemistry*
;
Medicine, Chinese Traditional
8.Characterization and Comparison Analysis of WHO Monographs on Selected Medicinal Plants and ISO Standards of Chinese Materia Medica.
Jing-Yi YANG ; Zhen SANG ; Rui WANG ; Yan-Hong SHI ; Yi-Ran HUANG
Chinese journal of integrative medicine 2023;29(6):540-548
Medicinal plants or Chinese materia medica (CMM) are now attracting worldwide attention as they have increasingly prominent advantages over chemical drugs in disease treatment and healthcare. Since the 1990s, World Health Organization (WHO) and International Organization for Standardization established the Technical Committee of Traditional Chinese Medicine (ISO/TC 249) have carried out the development of quality standards on medicinal plants or CMMs respectively, and a considerable number of monographs and international standards have been published. Since the two international organizations adhere to different principles, the standards they develop naturally have different emphasis. Driven by market demand and international trade, ISO mainly takes quality, efficacy and safety into consideration when developing standards, while WHO pays more attention to clinical practice, quality control and medication guidance. Up to now, there is a lack of comparative analysis on the records, background, principles, basic content, and main requirements of quality standards on medicinal plants or CMMs respectively published by WHO and ISO. Therefore, based on international standards of CMM developed by ISO/TC 249 platform and WHO Monographs on Selected Medicinal Plants, this paper systematically compares the purposes, selected principles, standard-developing process, basic content, and main quality requirements to summarize their similarities and differences, and find their merits, aiming to serve as a reference to the development of international standards for CMMs that helps them go global.
Materia Medica/therapeutic use*
;
Plants, Medicinal
;
Commerce
;
Internationality
;
Medicine, Chinese Traditional
;
Reference Standards
;
Drugs, Chinese Herbal/therapeutic use*
;
China
9.Chinese Medicine Regulates DNA Methylation to Treat Haematological Malignancies: A New Paradigm of "State-Target Medicine".
Feng-Lin SHEN ; Yan-Na ZHAO ; Xiao-Ling YU ; Bo-Lin WANG ; Xiao-Long WU ; Gao-Chen LAN ; Rui-Lan GAO
Chinese journal of integrative medicine 2022;28(6):560-566
Aberrant regulation of DNA methylation plays a crucial causative role in haematological malignancies (HMs). Targeted therapy, aiming for DNA methylation, is an effective mainstay of modern medicine; however, many issues remain to be addressed. The progress of epigenetic studies and the proposed theory of "state-target medicine" have provided conditions to form a new treatment paradigm that combines the "body state adjustment" of CM with targeted therapy. We discussed the correlation between Chinese medicine (CM) syndromes/states and DNA methylation in this paper. Additionally, the latest research findings on the intervention and regulation of DNA methylation in HMs, including the core targets, therapy status, CM compounds and active components of the Chinese materia medica were concisely summarized to establish a theoretical foundation of "state-target synchronous conditioning" pattern of integrative medicine for HMs, simultaneously leading a new perspective in clinical diagnosis and therapy.
DNA Methylation/genetics*
;
Drugs, Chinese Herbal
;
Hematologic Neoplasms/genetics*
;
Humans
;
Materia Medica
;
Medicine, Chinese Traditional
10.Homeopathy for COVID-19 in primary care: A randomized, double-blind, placebo-controlled trial (COVID-Simile study).
Ubiratan Cardinalli ADLER ; Maristela Schiabel ADLER ; Ana Elisa Madureira PADULA ; Livia Mitchiguian HOTTA ; Amarilys DE TOLEDO CESAR ; José Nelson Martins DINIZ ; Helen DE FREITAS SANTOS ; Edson Zangiacomi MARTINEZ
Journal of Integrative Medicine 2022;20(3):221-229
BACKGROUND:
Different homeopathic approaches have been used as supportive care for coronavirus disease 2019 (COVID-19) cases, but none has been tested in a clinical trial.
OBJECTIVES:
To investigate the effectiveness and safety of the homeopathic medicine, Natrum muriaticum LM2, for mild cases of COVID-19.
DESIGN, SETTING, PARTICIPANTS, AND INTERVENTIONS:
A randomized, double-blind, two-armed, parallel, single-center, placebo-controlled clinical trial was conducted from June 2020 to April 2021 in São-Carlos, Brazil. Participants aged > 18 years, with influenza-like symptoms and positive result from a real-time polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2 were recruited and randomized (1:1) into two groups that received different treatments during a period of at-home-isolation. One group received the homeopathic medicine Natrum muriaticum, prepared with the second degree of the fifty-millesimal dynamization (LM2; Natrum muriaticum LM2), while the other group received a placebo.
OUTCOME MEASURES:
The primary endpoint was time until recovery from COVID-19 influenza-like symptoms. Secondary measures included a survival analysis of the number and severity of COVID-19 symptoms (influenza-like symptoms plus anosmia and ageusia) from a symptom grading scale that was informed by the participant, hospital admissions, and adverse events. Kaplan-Meier curves were used to estimate time-to-event (survival) measures.
RESULTS:
Data from 86 participants were analyzed (homeopathy, n = 42; placebo, n = 44). There was no difference in time to recovery between two groups among participants who were reporting influenza-like symptoms at the beginning of monitoring (homeopathy, n = 41; placebo, n = 41; P = 0.56), nor in a sub-group that had at least 5 moderate to severe influenza-like symptoms at the beginning of monitoring (homeopathy, n = 15; placebo, n = 17; P = 0.06). Secondary outcomes indicated that a 50% reduction in symptom score was achieved significantly earlier in the homeopathy group (homeopathy, n = 24; placebo, n = 25; P = 0.04), among the participants with a basal symptom score ≥ 5. Moreover, values of restricted mean survival time indicated that patients receiving homeopathy might have improved 0.9 days faster during the first five days of follow-up (P = 0.022). Hospitalization rates were 2.4% in the homeopathy group and 6.8% in the placebo group (P = 0.62). Participants reported 3 adverse events in the homeopathy group and 6 in the placebo group.
CONCLUSION:
Results showed that Natrum muriaticum LM2 was safe to use for COVID-19, but there was no statistically significant difference in the primary endpoints of Natrum muriaticum LM2 and placebo for mild COVID-19 cases. Although some secondary measures do not support the null hypothesis, the wide confidence intervals suggest that further studies with larger sample sizes and more symptomatic participants are needed to test the effectiveness of homeopathic Natrum muriaticum LM2 for COVID-19.
TRIAL REGISTRATION
UMIN Clinical Trials Registry ID: JPRN-UMIN000040602.
COVID-19/therapy*
;
Double-Blind Method
;
Homeopathy
;
Humans
;
Influenza, Human/drug therapy*
;
Materia Medica/therapeutic use*
;
Primary Health Care
;
Treatment Outcome

Result Analysis
Print
Save
E-mail